Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

COVID-19 point-of-care tests can identify low-antibody individuals: In-depth immunoanalysis of boosting benefits in a healthy cohort

  • Michael Mallory
  • , Jennifer E. Munt
  • , Tara M. Narowski
  • , Izabella Castillo
  • , Edwing Cuadra
  • , Nora Pisanic
  • , Paul Fields
  • , John M. Powers
  • , Alexandria Dickson
  • , Rohan Harris
  • , Richard Wargowsky
  • , Seamus Moran
  • , Ahmed Allabban
  • , Kristin Raphel
  • , Timothy A. McCaffrey
  • , James D. Brien
  • , Christopher D. Heaney
  • , John E. Lafleur
  • , Ralph S. Baric
  • , Lakshmanane Premkumar

Producción científica: Article › revisión exhaustiva

2 Citas (Scopus)

Resumen

The recommended COVID-19 booster vaccine uptake is low. At-home lateral flow assay (LFA) antigen tests are widely accepted for detecting infection during the pandemic. Here, we present the feasibility and potential benefits of using LFA-based antibody tests as a means for individuals to detect inadequate immunity and make informed decisions about COVID-19 booster immunization. In a health care provider cohort, we investigated the changes in the breadth and depth of humoral and T cell immune responses following mRNA vaccination and boosting in LFA-positive and LFA-negative antibody groups. We show that negative LFA antibody tests closely reflect the lack of functional humoral immunity observed in a battery of sophisticated immune assays, while positive results do not necessarily reflect adequate immunity. After booster vaccination, both groups gain depth and breadth of systemic antibodies against evolving SARS-CoV-2 and related viruses. Our findings show that LFA-based antibody tests can alert individuals about inadequate immunity against COVID-19, thereby increasing booster shots and promoting herd immunity.

Idioma originalEnglish
Número de artículoeadi1379
PublicaciónScience advances
Volumen10
N.º24
DOI
EstadoPublished - jun 2024

Nota bibliográfica

Publisher Copyright:
© 2024 the Authors, some rights reserved;

Financiación

Acknowledgments: We thank the hcPs and staff at the GWUh department of emergency Medicine for contributions to this work. We are grateful for the in-kind support of Adaptive Biotechnologies, inc. for the immunoSeQ assay. We acknowledge cellex, nc, USA for donating cellex qSARS-cov-2 igG/igM Rapid test kits for this study. t.A.M. is grateful for the support of the St. laurent institute and the Ulvi and Reykhan Kasimov Family. Funding: this work was supported by the nci Serological Sciences network (4U54cA260543 to R.S.B. and l.P., U01cA260469 to c.d.h., and U01cA260541 and U01cA260541-02S1 to A.d. and J.d.B.). the funders had no role in study design, data collection, decision to publish, or preparation of the manuscript. Acknowledgments: We thank the hcPs and staff at the GWUh department of emergency Medicine for contributions to this work. We are grateful for the in-kind support of Adaptive Biotechnologies, inc. for the immunoSeQ assay. We acknowledge cellex, nc, USA for donating cellex qSARS-cov-2 igG/igM Rapid test kits for this study. t.A.M. is grateful for the support of the St. laurent institute and the Ulvi and Reykhan Kasimov Family. Funding: this work was supported by the nci Serological Sciences network (4U54cA260543 to R.S.B. and l.P., U01cA260469 to c.d.h., and U01cA260541 and U01cA260541-02S1 to A.d. and J.d.B.). the funders had no role in study design, data collection, decision to publish, or preparation of the manuscript. Authors contributions: conceptualization: J.e.l., R.S.B., and l.P. Methodology: M.M., J.e.M., t.M.n., i.c., e.c., n.P., P.F., J.M.P., A.d., t.A.M., J.d.B., c.d.h., J.e.l., R.S.B., and l.P. investigation: M.M., J.e.M., t.M.n., i.c., e.c., n.P., P.F., J.M.P., A.d., R.h., R.W., S.M., A.A., K.R., t.A.M., J.d.B., c.d.h., J.e.l., R.S.B., and l.P. visualization: M.M., J.e.M., and l.P. Supervision: J.d.B., c.d.h., J.e.l., R.S.B., and l.P. Writing—original draft: J.e.l. and l.P. Writing—review and editing: M.M., J.e.M., t.M.n., i.c., e.c., n.P., P.F., J.M.P., A.d., R.h., R.W., S.M., A.A., K.R., t.A.M., J.d.B., c.d.h., J.e.l., R.S.B., and l.P. Competing interests: t.A.M. has an equity interest in true Bearing diagnostics inc., a diagnostics company developing RnA biomarkers for various diseases but unrelated to the present project. R.S.B. is a member of advisory boards for vaxArt, takeda, and invivyd and has collaborative projects with Gilead, Moderna, J&J, and hillevax, focused on unrelated projects. R.S.B. is an inventor on methods and uses of mouse-adapted SARS-cov-2 viruses and SARS-cov2 nanoluciferase viruses (US patent US11225508B1). P.F. was used and has stock options with Adaptive Biotechnologies. the authors declare that they have no other competing interests. Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials.

FinanciadoresNúmero del financiador
St. laurent institute
Ulvi and Reykhan Kasimov FamilyU01cA260541, U01cA260469, U01cA260541-02S1, 4U54cA260543

    ODS de las Naciones Unidas

    Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

    1. Good health and well being
      Good health and well being

    ASJC Scopus subject areas

    • General

    Acceder al documento

    Otros archivos y enlaces

    Huella

    Profundice en los temas de investigación de 'COVID-19 point-of-care tests can identify low-antibody individuals: In-depth immunoanalysis of boosting benefits in a healthy cohort'. En conjunto forman una huella única.
    Ver la huella completa

    Citar esto